Launch One Acquisition's (LPAA) merger target Minovia Therapeutics said Monday it has been granted US Food and Drug Administration fast-track designation for its lead investigational compound MNV-201, which is intended as a treatment for Pearson Syndrome.
The company said the FDA also granted the drug candidate rare pediatric disease designation. The drug candidate is in phase 2 clinical trials for the treatment of the disease, the company said.
Launch One, a blank-check company, is expected to close its business combination with Minovia in late 2025, the company said.
Pearson Syndrome is a rare genetic disorder that leads to bone marrow failure, metabolic crises, and organ dysfunction.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。